The biggest strategic debate in autoimmune cell therapy is no longer whether cell therapy has a role in autoimmune disease. The discussion has shifted toward which platform can ultimately deliver durable immune reset, acceptable safety, operational scalability, and broad patient access.
Autologous CAR-T therapies have generated some of the strongest clinical signals to date. At the same time, allogeneic platforms are attempting to solve manufacturing and access challenges, while in vivo approaches aim to eliminate many of the logistical constraints associated with traditional cell therapies altogether.
As more clinical data emerges, developers are increasingly evaluating the trade-offs between these approaches.
Key Takeaways:
- Autologous therapies currently possess the greatest clinical maturity in autoimmune disease
- Allogeneic therapies are being developed to improve scalability, consistency, and accessibility
- In vivo approaches aim to engineer immune cells directly inside the patient, potentially reducing manufacturing burden
- Safety requirements in autoimmune disease are substantially different from oncology and influence platform selection
- No single modality has emerged as the definitive winner, making platform evaluation a major strategic priority
What Are Autologous, Allogeneic and In Vivo Cell Therapies?
Autologous Cell Therapy
Autologous therapies use a patient's own cells. These cells are collected, modified outside the body, and then returned to the patient. Many autoimmune CAR-T programs currently follow this model.
Allogeneic Cell Therapy
Allogeneic therapies use cells from a donor rather than the patient. Developers hope these off-the-shelf products can improve manufacturing scalability and increase treatment accessibility.
In Vivo Cell Therapy
In vivo approaches seek to engineer immune cells directly inside the patient using delivery technologies such as RNA or DNA-based systems. These platforms aim to avoid many traditional cell manufacturing steps.
How Do the Modalities Compare?
Modality
Key Strength
Key Challenge
Autologous
Clinical maturity and patient-specific approach
Manufacturing complexity
Allogeneic
Off-the-shelf scalability
Persistence and immune compatibility
In Vivo
Potentially simplified delivery and lower manufacturing burden
Safety and delivery control
Why Are Autologous Therapies Leading Today?
Many developers view autologous approaches as the current benchmark because they have generated some of the most mature autoimmune clinical datasets.
Companies such as Cabaletta Bio and Kyverna Therapeutics have helped establish confidence that deep immune intervention can produce meaningful clinical responses in autoimmune indications. The field has progressively moved from isolated case reports toward larger clinical studies and increasingly mature datasets.
However, these therapies require individualized manufacturing, which creates operational and cost challenges as developers seek to address larger patient populations.
Why Are Developers Investing in Allogeneic Platforms?
For many organizations, scalability is becoming the next major challenge.
Allogeneic approaches are attractive because they can potentially be manufactured in advance and delivered as off-the-shelf products. This may improve accessibility, reduce manufacturing timelines, and support broader adoption.
Companies including Artiva Biotherapeutics, Nkarta, Glycostem Therapeutics and Orca Bio are exploring various allogeneic strategies designed to balance efficacy, safety, and scalability.
The challenge remains demonstrating durable responses while effectively managing immune compatibility issues.
Why Is In Vivo Cell Therapy Generating So Much Attention?
Few topics are attracting as much interest as in vivo cell engineering.
Rather than manufacturing cells outside the body, these approaches aim to generate therapeutic activity directly within the patient. Developers believe this could significantly simplify production and potentially improve access across larger autoimmune populations.
Companies such as Sail Biomedicines, CPTx, Able Sciences, and Overland Therapeutics are helping drive discussion around the future role of in vivo immune reset strategies.
However, safety remains a central challenge. Because autoimmune patients are often clinically stable and may live for decades, regulators and clinicians may have lower tolerance for toxicity than in oncology settings.
The Myth VS the Reality
Myth: One modality will ultimately replace all others.
Reality: Different autoimmune diseases, patient populations, and healthcare systems may require different approaches. Developers increasingly recognize that multiple modalities may coexist, each serving distinct clinical and commercial needs.
What Industry Leaders Are Evaluating
- Across the field, several themes are emerging:
- Which modality offers the best safety profile?
- How durable are responses?
- Can manufacturing scale economically?
- Which approaches support broad community adoption?
- How should developers benchmark autologous, allogeneic, and in vivo platforms?
- What role will biomarkers play in modality selection
These questions form the basis of ongoing discussions throughout the autoimmune cell therapy ecosystem.
What This Means for Developers
Platform selection is becoming a strategic decision that extends beyond science alone. Developers must consider manufacturing readiness, clinical operations, patient accessibility, reimbursement potential, and long-term commercial viability alongside efficacy data. Organizations that clearly understand these trade-offs will be better positioned as the autoimmune cell therapy market continues to mature.
![CB-CDx-0690-min-scaled11[1]](https://cell-therapy-autoimmune-disease.com/wp-content/uploads/sites/286/2024/06/CB-CDx-0690-min-scaled111.jpg "CB-CDx-0690-min-scaled11[1]")
Explore the Agenda
Discover the latest clinical breakthroughs, translational advances, and commercialization strategies shaping autoimmune cell therapy.
Partner With Us
Connect with the industry's leading autoimmune cell therapy developers as they navigate the next phase of clinical and commercial growth.
Join Cell Therapy & Autoimmune Leaders
Network with 100+ biotech, pharma, academic and clinical experts advancing cell therapies beyond oncology.